Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Core Insights - Clene Inc. and its subsidiary Clene Nanomedicine Inc. are participating in a panel discussion focused on neurodegenerative diseases at the Maxim Growth Summit, highlighting their commitment to addressing challenging therapeutic areas [1][2] - The company is advancing its investigational therapy CNM-Au8, which targets mitochondrial function and the NAD pathway to improve neuronal health and combat diseases like ALS and MS [2] Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland [2] - The company specializes in therapies aimed at improving mitochondrial health and protecting neuronal function, specifically for neurodegenerative diseases such as ALS, Parkinson's disease, and MS [2] Product Information - CNM-Au8 is a first-in-class investigational therapy designed to enhance the survival and function of central nervous system cells by reducing oxidative stress and targeting mitochondrial function [2]